Two recently completed clinical trials, in separate disease settings, utilized tumor-reactive mAbs to successfully target and treat the tumors: (1) the combination of dinutuximab with IL-2, GM-CSF, and isotretinoin for patients with high-risk neuroblastoma (1) and (2) rituximab for the treatment of patients with low-tumor burden follicular lymphoma (FL) (2). Here, CSF2 is linked to follicular lymphoma.